Our study shows that the PDE4 inhibitor roflumilast, a prescription drug for COPD, can be an attractive therapeutic modality to prevent or treat CKD associated with NAFLD. Here, PDE4A is linked to metabolic dysfunction-associated steatotic liver disease.